Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Consensus Recommendation of “Buy” by Analysts

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $10.1667.

A number of equities analysts have commented on the company. Zacks Research raised Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 18th. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. HC Wainwright assumed coverage on shares of Marker Therapeutics in a research report on Monday, December 8th. They set a “buy” rating and a $10.00 price target on the stock. Wall Street Zen cut shares of Marker Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Tuesday, December 16th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics in the 3rd quarter valued at $25,000. Two Sigma Investments LP bought a new position in Marker Therapeutics in the third quarter valued at about $33,000. Finally, Jane Street Group LLC acquired a new stake in Marker Therapeutics in the second quarter worth about $33,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Trading Up 1.6%

Shares of Marker Therapeutics stock opened at $1.28 on Monday. The stock has a market capitalization of $21.34 million, a price-to-earnings ratio of -1.04 and a beta of 1.35. The firm’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.22. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.57. The company had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. As a group, equities research analysts predict that Marker Therapeutics will post -0.65 EPS for the current year.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.